Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16383984 | 0.85 | ADORA1 (0.47) | PDE9AKDM4ECLK1DYRK1ANCOA3 | |
| SCHEMBL16383982 | 0.84 | CLK1 (0.39) | PDE9AKDM4EALDH1A1CLK1DYRK1A | |
| SCHEMBL28428018 | 0.83 | SQOR (0.50) | PDE9AKDM4EALDH1A1ALOX5NCOA3 | |
| SCHEMBL28345506 | 0.81 | FASN (0.43) | KDM4EALDH1A1CLK1DYRK1AALOX5 | |
| SCHEMBL16383955 | 0.81 | CTSS (0.46) | KDM4EALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL16984847 | 0.81 | ALDH1A1 (0.47) | PDE9AKDM4EALDH1A1HSD17B10ALOX15 | |
| SCHEMBL16384089 | 0.81 | CLK1 (0.37) | PDE9AKDM4EALDH1A1CLK1DYRK1A | |
| SCHEMBL29489130 | 0.80 | MCL1 (0.47) | KDM4ECLK1DYRK1ANCOA3ALOX15 | |
| SCHEMBL31457372 | 0.80 | CLK1 (0.49) | KDM4EALDH1A1CLK1DYRK1ANCOA3 | |
| SCHEMBL28869476 | 0.80 | CLK1 (0.49) | KDM4EALDH1A1CLK1DYRK1ANCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3611175-B1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | YAMAMOTO CHEMICALS INC (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-11174274-B2 | Naphthalocyanine compound, method for producing same, and use thereof | YAMAMOTO CHEMICALS, INC. (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210107924-A1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | YAMAMOTO CHEMICALS, INC. (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3611175-A1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | Yamamoto Chemicals, Inc. (JP) | 2020-02-19 | — | — | EP | disclosed |
| CN-101149576-B | Electrostatic charge developing toner, developer using the same, developer cartridge, and image forming apparatus | FUJI XEROX CO LTD | 2010-05-26 | — | — | CN | disclosed |
| CN-101149576-A | Electrostatic charge developing toner, developer using the same, developer cartridge, and image forming apparatus | FUJI XEROX CO LTD (JP) | 2008-03-26 | — | — | CN | disclosed |
| US-20080070142-A1 | Toner for electrostatic charge development, and developer for electrostatic charge development using the same, developer cartridge for electrostatic charge development and image forming apparatus | FUJI XEROX CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070142-A1 | Toner for electrostatic charge development, and developer for electrostatic charge development using the same, developer cartridge for electrostatic charge development and image forming apparatus | FUJI XEROX CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070142-A1 | Toner for electrostatic charge development, and developer for electrostatic charge development using the same, developer cartridge for electrostatic charge development and image forming apparatus | FUJI XEROX CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107924-A1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | MRPS9, INTS9, RPL19 | PDE9A 2630/4885KDM4E 3081/4885ALDH1A1 2361/4885 |
| US-11174274-B2 | Naphthalocyanine compound, method for producing same, and use thereof | MRPS9, INTS9, RPL19 | PDE9A 2630/4885KDM4E 3081/4885ALDH1A1 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.